AOD9604 (AOD9604) by Hangzhou Pepsource Biomedical Co.,LTD: new bulk ingredient listing
AOD9604 (AOD9604) by Hangzhou Pepsource Biomedical Co.,LTD: new bulk ingredient listing. Dated 112 days ago, it serves as a historical benchmark. Score 15/100. As of 2026-11-03, from U.S. FDA National Drug Code (NDC) Directory via openFDA.
Data as of · Compiled by Zalwin from U.S. FDA National Drug Code (NDC) Directory via openFDA
Free preview: all 9 published fields of this record are shown below. Locked: 313 related FdaNdcDirectoryPulse records and the 5-column CSV export.
| Field | Value |
|---|---|
| Generic name | AOD9604 |
| NDC | 87831-012 |
| Labeler | Hangzhou Pepsource Biomedical Co.,LTD |
| Product type | BULK INGREDIENT |
| Approval pathway | BULK INGREDIENT |
| Dosage form | POWDER |
| Active ingredients | LAT-8881 5 g/5g |
| Marketing start | 2026-07-16 |
| Package configurations | 1 |
| Peer records CSV (314 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch AOD9604 (AOD9604) by Hangzhou Pepsource Biomedical Co.,LTD
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock AOD9604 (AOD9604) by Hangzhou Pepsource Biomedical Co.,LTD + all 314 records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Product · Labeler · Pathway · Form · Listed · official source URL
- Source agency: U.S. FDA National Drug Code (NDC) Directory via openFDA
- Record date: 2026-07-16
- Data refreshed: 2026-11-03
- Refunds on request within 14 days
Top FdaNdcDirectoryPulse records (BULK INGREDIENT first): Ensitrelvir Fumaric Acid (Ensitrelvir Fumaric Acid) by Shion · alirocumab (alirocumab) by SAMSUNG BIOLOGICS Co., Ltd. · Dapoxetine HCl (Dapoxetine HCl) by AX Pharmaceutical Corp · LEFLUNOMIDE (LEFLUNOMIDE) by MAEDA INC · Slu PP 915 (Slu PP 915) by ETERNAL WEALTH (CHINA) LIMITED · Browse all by state and category →
LIVE PUBLIC DATA Source: U.S. FDA National Drug Code (NDC) Directory via openFDA · Last refreshed: Tue, 03 Nov 2026 18:09:00 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: AOD9604 (AOD9604) by Hangzhou Pepsource Biomedical Co.,LTD and 314 BULK INGREDIENT peers
- BULK INGREDIENT FdaNdcDirectoryPulse records like this one: 314
- Timing: Low: older than 30 days
- Estimated pipeline if you contact every BULK INGREDIENT peer: $62,800 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
15 / 100 Launch Signal Score
What is the FdaNdcDirectoryPulse record for AOD9604 (AOD9604) by Hangzhou Pepsource Biomedical Co.,LTD?
AOD9604 by Hangzhou Pepsource Biomedical Co.,LTD: new bulk ingredient listing (BULK INGREDIENT) starting 2026-07-16.
How does AOD9604 (AOD9604) by Hangzhou Pepsource Biomedical Co.,LTD compare to other FdaNdcDirectoryPulse records?
It is 112 days old; check the official source for later updates before acting. Its Launch Signal Score of 15/100 is modest; treat it as background rather than a priority.
AOD9604 (AOD9604) by Hangzhou Pepsource Biomedical Co.,LTD vs. top 3 peers
| Organization | Location | Record date |
|---|---|---|
| AOD9604 (AOD9604) by Hangzhou Pepsource Biomedical Co.,LTD | BULK INGREDIENT | 2026-07-16 |
| Ifosfamide | HUMAN PRESCRIPTION DRUG | 2026-09-04 |
| Rifadin | HUMAN PRESCRIPTION DRUG | 2026-08-03 |
| Oxygen | HUMAN PRESCRIPTION DRUG | 2026-07-15 |
Related records
- Ifosfamide
- Rifadin
- Oxygen
- Water (Water) by Siegfried Hameln GmbH: new drug for further processing listing
- Donanemab (Donanemab) by BSP Pharmaceuticals S.p.A.: new drug for further processing listing
- apitegromab (apitegromab) by Catalent Pharma Solutions, LLC: new drug for further processing listing
- zilganersen (zilganersen) by Patheon Italia S.p.A.: new drug for further processing listing
- teduglutide (teduglutide) by Patheon Italia S.p.A.: new drug for further processing listing
- rusfertide (rusfertide) by Patheon Italia S.p.A.: new drug for further processing listing
- rusfertide (rusfertide) by Patheon Italia S.p.A.: new drug for further processing listing
- rusfertide (rusfertide) by Patheon Italia S.p.A.: new drug for further processing listing
- rusfertide (rusfertide) by Patheon Italia S.p.A.: new drug for further processing listing
How to monitor AOD9604 (AOD9604) by Hangzhou Pepsource Biomedical Co.,LTD and peer other records
Get new FdaNdcDirectoryPulse records like AOD9604 (AOD9604) by Hangzhou Pepsource Biomedical Co.,LTD by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new listings in your categories
FdaNdcDirectoryPulse emails new drug listings matching your pathway and product type.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
Listing data comes from the FDA NDC directory via openFDA; a listing is not an FDA approval or endorsement and may be updated or withdrawn. Informational only; not medical advice.